{"entity":{"id":"nct07745361","kind":"trial","name":"Study of Oral MRT-2359 With Apalutamide in Prostate Cancer","aka":[],"tldr":"A phase 2 trial of Apalutamide in prostate cancer, run by Monte Rosa Therapeutics, Inc, now recruiting.","summary":"Study of Oral MRT-2359 With Apalutamide in Prostate Cancer is a phase 2 interventional study registered as NCT07745361 by Monte Rosa Therapeutics, Inc, with 25 participants planned, started 2026-08 and due to reach its primary completion in 2027-10. Interventions recorded: Oral MRT-2359, Apalutamide. Conditions listed: Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer, Prostate Cancer, Prostate Cancer (Adenocarcinoma). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07745361","url":"https://clinicaltrials.gov/study/NCT07745361"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["apalutamide"],"companies":["monte-rosa"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07745361","phase":"2","setting":"MODeFIRe-1 (Molecular Degrader for Inhibitor Resistance): A Phase 2, Open-Label, Multicenter Study of Oral MRT-2359 in Combination With Apalutamide in Patients With Castration-Resistant Prostate Cancer","sponsor":"Monte Rosa Therapeutics, Inc","enrolled":25,"outcomes":[]},"route":"/trials/nct07745361/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"apalutamide","kind":"drug","name":"Apalutamide","route":"/drugs/apalutamide/"}],"company":[{"id":"monte-rosa","kind":"company","name":"Monte Rosa Therapeutics","route":"/companies/monte-rosa/"}]}}